

REMARKS

Claims 1-28 are pending in the present application. The Office Communication states that the application fails to comply with the requirements for patent applications containing nucleotide and/or amino acid disclosures as set forth in 37 C.F.R. § 1.821-1.825. A clean copy of a substitute specification and a marked-up version to show changes made to the original specification are included herewith. The substitute specification incorporates sequence identification numbers to all nucleotide/amino acid sequence disclosures in the original specification and corrects several minor typographical errors. These amendments are found on pages 3, 4, 5, 6, 7, 38, 45, 46, 48 and 50 of the substitute specification.

In addition, the descriptions of Figures 9 and 10 on pages 5 and 6 of the substitute specification have been amended to incorporate the names of the strains of *H. ducreyi* indicated in the figures and, where relevant, the sequence identifier. These amendments are supported by the Figures themselves as they were originally filed.

Applicants submit that the amendments to the specification present no new matter and replacement of the original specification with the enclosed substitute specification is respectfully requested.

A substitute Sequence Listing in computer-readable form (CRF) and a paper copy of the substitute Sequence Listing are provided herein, incorporating additional nucleotide/amino acid sequences that were disclosed in the specification as filed but were not included in the original Sequence Listing. Applicants state that the subject matter of the computer-readable and the paper copies of the substitute Sequence Listing are the same and present no new matter beyond the specification as originally filed. Entry of the paper and computer-readable copies of the substitute Sequence Listing is respectfully requested.

Applicants believe that that the present application is now in condition for substantive examination, which action is respectfully requested.

Attorney Docket No. 5470.269
Application Serial No.: 10/030,529
Filed: May 6, 2002
Page 4 of 4

Applicants believe that no fee is due with this response, however, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,



Karen A. Magri
Registration No. 41,965

Correspondence Address:


Myers, Bigel, Sibley & Sajovec
P.O. Box 37428
Raleigh, NC 27627
Telephone: 919/854-1400
Facsimile: 919/854-1401

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR §1.10

"Express Mail" mailing label number: EV 353611206 US

Date of Deposit: October 2, 2003

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Cathy A. Schetzina